Dr. Machiels on Ongoing Trial of Pembrolizumab Plus Chemoradiation in HNSCC

Jean-Pascal Machiels, MD
Published: Wednesday, Jun 14, 2017



Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses an ongoing clinical trial of pembrolizumab (Keytruda) combined with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

Data in the recurrent setting suggest that anti–PD-1 therapy improves survival, as seen with nivolumab (Opdivo) and pembrolizumab (Keytruda). Therefore, researchers are interested in improving outcomes with the combination of pembrolizumab plus chemoradiation. 

 


Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses an ongoing clinical trial of pembrolizumab (Keytruda) combined with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

Data in the recurrent setting suggest that anti–PD-1 therapy improves survival, as seen with nivolumab (Opdivo) and pembrolizumab (Keytruda). Therefore, researchers are interested in improving outcomes with the combination of pembrolizumab plus chemoradiation. 

 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x